

Amendments to the Claims

The following Listing of Claims shows the claims as currently amended, and will replace all previous versions in the subject application:

LISTING OF CLAIMS

5

Claims 1-52 (canceled).

53 (new). A compressed pharmaceutical dosage form comprising
a first segment comprising a composition containing an effective amount of one or more drugs,
and

10 a second segment contacting said first segment, said second segment comprising an immediate
release composition substantially free of drug, said second segment forming an outer segment of said
dosage form and providing a breaking segment for breaking through said second segment without
substantial consequent breakage of the first segment, wherein said dosage form comprises a score greater
than 50% through the maximum height of one of said first or second segments.

15 54 (new). A compressed pharmaceutical dosage form having its height greater than its width and
configured as

a first segment comprising a composition containing an effective amount of one or more drugs,
and

20 at least one additional segment comprising a composition containing an effective amount of a
drug or drugs, and

a second segment contacting said first segment, said second segment comprising an immediate
release composition substantially free of drug and forming an inner inactive segment that is adjacent
above and below said first and said additional segment,

25 wherein the compositions of said first and said additional segment and the drug or drugs contained in said
compositions are physically and chemically compatible with one another, and

wherein the terms "height" and "width" and "above" and "below" refer to the position of said dosage form
in a tablet die after tablet compression has been completed but before said tablet has been ejected from
said die.

55 (new). A compressed pharmaceutical dosage form having its height greater than its width and configured as

a first segment comprising a composition containing an effective amount of one or more drugs,

and

at least one additional segment comprising a composition containing an effective amount of a drug or drugs, and

a second segment contacting said first segment, said second segment comprising an immediate release composition substantially free of drug and forming an inner inactive segment that is adjacent above and below said first and said additional segment,

wherein said dosage form

- i) lacks a semi-permeable membrane coating,
- ii) lacks an osmotically active component to effect intrinsic altered release, or
- iii) lacks a drug over-coating,

wherein the terms "height" and "width" and "above" and below" refer to the position of said dosage form in a tablet die after tablet compression has been completed but before said tablet has been ejected from said die.

Claim 56 (new). A compressed pharmaceutical dosage form having its height greater than its width and configured as

a first segment comprising a composition containing an effective amount of one or more drugs (A), and

at least one additional segment comprising a composition containing an effective amount of a drug or drugs (B) or (C), and

a second segment contacting said first segment, said second segment comprising an immediate release composition substantially free of drug and forming an inner inactive segment that is adjacent above and below said first and said additional segment,

wherein said dosage form comprises a tablet structure selected from the group consisting of A-I-A; A-I-B; A-I-A-I; A-I-B-I; A-I-B-I-A; A-I-B-I-B; A-I-B-I-C; and A-B-I-C wherein

"A" represents an active segment comprising a first active drug or combination of more than one active drug;

"B" represents an active segment comprising a second active drug or combination of active drugs;

"C" represents an active segment comprising a third active drug or combination of drugs; and

“I” represents an inactive segment substantially free of active drug or combination of active drugs, and

wherein the terms “height” and “width” and “above” and below” refer to the position of said dosage form in a tablet die after tablet compression has been completed but before said tablet has been ejected from said die.

Claim 57 (new). The dosage form of claim 56, wherein the compositions containing a drug or drugs, and the drug or drugs contained in said compositions are physically or chemically compatible with one another.

Claim 58 (new). The dosage form of claim 56, wherein said dosage form lacks a semi-permeable membrane coating.

Claim 59 (new). The dosage form of claim 56, wherein said dosage form lacks an osmotically active component to effect intrinsic altered release, or

Claim 60 (new). The dosage form of claim 56, wherein said dosage form lacks a drug over-coating.

Claim 61 (new). The dosage form of claim 53 wherein said composition containing a drug or drugs is a controlled release composition selected from the group consisting of delayed release, modified release, sustained-release, quick dissolve oral or buccal release, and solubility modifiers.

Claim 62 (new). The dosage form of claim 56 wherein said composition containing a drug or drugs is a controlled release composition selected from the group consisting of delayed release, modified release, sustained-release, quick dissolve oral or buccal release, and solubility modifiers.

Claim 63 (new). The dosage form of claim 56 wherein at least one of said drug or drugs in said first segment is different than at least one of said drug or drugs in said additional segment.

Claim 64 (new). The dosage form of claim 56 wherein the height of said inner segment is greater than a combined height of said first segment and said additional segment.

Claim 65 (new). The dosage form of claim 56 comprising a separation mark oriented substantially horizontally on or within the inner segment to guide tablet breaking through the inner segment without breaking through the first or additional segment, said separation mark selected from the group consisting of a score, perforation, color, printed marking or indicia, and gelatin band.

Claim 66 (new). The dosage form of claim 65 wherein the separation mark is a score having a depth of at least 70% of the horizontal dimension or width of the segment.

Claim 67 (new). The dosage form of claim 53, said dosage form comprising a separation mark positioned parallel to the vertical axis of the dosage form.

5 Claim 68 (new). The pharmaceutical tablet of claim 53 comprising in at least one segment a colorant for visually distinguishing said segment from another segment.

Claim 69 (new). The pharmaceutical tablet of claim 56 comprising in at least one segment a colorant for visually distinguishing said segment from another segment.

10 Claim 70 (new). The dosage form of claim 56 wherein said inner segment has an effective height of at least 0.5 mm.

Claim 71 (new). The dosage form of claim 70 wherein said inner segment has an effective height of about 1.5 mm to about 3 mm.

15 Claim 72 (new). A method of breaking a pharmaceutical dosage form, said method comprising the steps of
 providing a segmented dosage form of claim 53, and
 applying pressure to said dosage form in order to break through the second segment without breaking through a segment adjacent to said second segment.

20 Claim 73 (new). A method of breaking a pharmaceutical dosage form, said method comprising the steps of
 providing a segmented dosage form of claim 56, and
 applying pressure to said dosage form in order to break through the inactive segment without breaking through a segment adjacent to said inactive segment.

25 Claim 74 (new). A method of administering a partial dose of a drug, said method comprising the steps of
 providing a dosage form of claim 53,
 breaking said dosage form through the second segment to form two or more tablets without breaking a segment adjacent to said second segment, and
 administering at least one of said tablets to a patient.

Claim 75 (new). A method of administering a partial dose of a drug, said method comprising the steps of

providing a dosage form of claim 56,

breaking said dosage form through the inactive segment to form two or more tablets without

5 breaking a segment adjacent to said inactive segment, and

administering at least one of said tablets to a patient.

Claim 76 (new). The dosage form of claim 53 wherein said tablet is further covered with an inert or pharmaceutically inactive composition.

10 Claim 77 (new). The dosage form of claim 76 wherein the inert or pharmaceutically inactive composition is a capsule.

Claim 78 (new). The dosage form of claim 56 wherein said tablet is further covered with an inert or pharmaceutically inactive composition.

Claim 79 (new). The dosage form of claim 78 wherein the inert or pharmaceutically inactive composition is a capsule.

15